Epicatechin enhances anti-proliferative effect of bleomycin in ovarian cancer cell

Message:
Abstract:
Background And Aim
Bleomycin (BLM) is an anti-cancer drug widely used in the treatment of cancer. BLM causes several side effects related to DNA and cellular damage. The aim of this study was investigated the effects of tea polyphenol epicatechin on anti-proliferative effects induced by bleomycin in human normal skin and human ovarian cancer cells.
Methods
Human ovarian cancer cell (SKOV-3) and human non-malignant fibroblast cell (HFFF2) were treated with epicatechin at various concentrations (10, 25 and 50 µM) and BLM alone and with their combinations, further their effects on cell viability were evaluated.
Results
The combined treatment of epicatechin with BLM enhanced significantly inhibition of cell growth in comparison to BLM alone in cancer cell. Epicatechin enhanced significantly cytotoxicity induced by BLM with 83% at dose 50 µM, while it was 92% in BLM-treated cells. Epicatechin was not showed any cytotoxicity on HFFF2 cells. COCLUSION: Study suggests that epicatechin chemosensitize the ovarian cancer cell to BLM-induced growth inhibition without any toxicity on normal cell.
Language:
English
Published:
Research in Molecular Medicine, Volume:1 Issue: 3, Nov 2013
Pages:
24 to 27
magiran.com/p1227266  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 1,390,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
In order to view content subscription is required

Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!